A drug to boost female sex drive could be worth billions to the company that manages to get it approved by the FDA. Recently, two new treatments have made strides towards that goal. But some are skeptical of the real value of such a drug to the women it's supposed to help.
With two fast-paced careers, a toddler, and another baby on the way, Meghan and Jeremy Wilker have let their marriage drop to the bottom of their to-do list. Can REDBOOK Love Network expert Jane Greer, Ph.D., help them finally make time for each other?
Meghan and Jeremy Wilker are both at the top of their career game. Meghan, 32, runs a company that constructs Websites, and Jeremy, 38, recently launched two companies: one sells fine-art photo prints online; the other is a digital photo...
Except an FDA advisory panel saw things differently. Finding numerous problems with the evidence for the drug's effectiveness and safety, experts on the panel voted against approving it. Procter & Gamble, the company responsible for Intrinsa, withdrew its application. Procter & Gamble is a WebMD sponsor.
Now the frontrunner in the race to market the first prescription drug for low female sex drive is Boehringher-Ingelheim Pharmaceuticals. It has a drug called flibanserin in phase III clinical trials, the final phase of drug testing required for FDA approval. The company is a WebMD sponsor.
Flibanserin is a bit mysterious. It is a kind of antidepressant, but it hasn't been approved previously for any use. Boehringher-Ingelheim is saying little publicly about the drug. The company declined WebMD's request to interview a company representative, instead issuing a prepared statement. The statement does not explain how the drug is supposed to work, other than that "flibanserin is a molecule acting on the central nervous system and is not a hormone product."
Another drug, called bremelanotide, is in development for low female sex drive and male erectile dysfunction at the same time. Both potential uses are being tested in phase II clinical trials, which are early studies to assess how well a drug works and how safe it is.
Bremelanotide is a new chemical created in the laboratory. It's given in the form of a nasal spray, and it acts on the central nervous system.
"It's actually working in a region of the brain called the hypothalamus, which is known to be involved in sexual arousal in both men and women," says Carl Spana, PhD, CEO of Palatin Technologies, the company researching bremelanotide.